Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Burzynski Research Institute Inc

+ Add to Watchlist


0.1100 USD 0.00000.00%

As of 14:44:12 ET on 03/02/2015.

Snapshot for Burzynski Research Institute Inc (BZYR)

Open: 0.1100 Day's Range: 0.1100 - 0.1100 Volume: 7,000
Previous Close: 0.1100 52wk Range: 0.0300 - 0.5000 1-Yr Rtn: +37.50%

Stock Chart for BZYR

No chart data available.
  • BZYR:US 0.1100
  • 1D
  • 1M
  • 1Y
Interactive BZYR Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for BZYR

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. SPX -
Earnings Per Share (ttm) -0.0400
Est. EPS -
Est. PEG Ratio -
Market Cap (M USD) 14.46
Shares Outstanding (M) 131.45
30 Day Average Volume 1,098
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/29/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for BZYR

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for BZYR

Burzynski Research Institute, Inc. manufactures medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids. The Company is conducting clinical trials of Antineoplastons relating to the treatment of cancer. Burzynski is seeking Food and Drug Administration approval for the sale of Antineoplastons.

Stanislaw R BurzynskiChairman/PresidentTomasz JanickiVP:Clinical Trials
Patryk P GoscianskiTreasurer/Secretary
More Company Profile & Key Executives for BZYR

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil